Clinical Trial

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed Choroideremia (CHM).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-07-20; most recent amendment 2025-05-20.
Status change: Recruiting → Active, Not Recruiting 2023-01-18
Trial Details
NCT Number NCT04483440
Lead Sponsor 4D Molecular Therapeutics
Conditions Choroideremia
Enrollment 13 participants
Start Date 2020-06-02
Primary Completion 2027-05-26 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-22